As key genetic factors contribute to hepatotoxicity, the PNPLA3 genetic variant is linked not only to higher risk for benign steatosis, but also MASH, fibrosis, cirrhosis and end‐stage HCC [16]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.